Document is current
Any future updates will be listed below
-
Authors
Shah, Krisha https://orcid.org/0009-0008-3059-2226
Herzog, Rubén https://orcid.org/0000-0002-3498-5819
Swann, Alan C. https://orcid.org/0000-0001-9879-6198
O’Brien, Brittany
Balakrishnan, Rahul https://orcid.org/0009-0000-5162-193X
Mathew, Sanjay J.
Murphy, Nicholas https://orcid.org/0000-0003-1805-3082
- License Information
-
More Information
Article History
Received: 6 September 2025
Revised: 1 June 2026
Accepted: 16 June 2026
First Online: 4 July 2026
Ethics
Competing interests: S.J. Mathew has received consultant fees or research support from Abbott, Almatica Pharma, Autobahn Therapeutics, AtaiBeckley, Boehringer-Ingelheim, Clexio Biosciences, Definium Therapeutics, Douglas Pharmaceuticals, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, Liva Nova, Merck, Motif Neurotech, Neumora, Newleos, Relmada Therapeutics, Sage Therapeutics, Sensorium Biosciences, Signant Health, Sunovion Pharmaceuticals, Supernus, Syndeio Biosciences, and Xenon Pharmaceuticals. N. Murphy has received research funding from Tech Innosphere Eng Ltd, and Syndeio Biosciences (formerly Gate Neuroscience Inc).
